



NEWS RELEASE

KETAMINE ONE FEATURES BIOSTRAP AS PART OF INAUGURAL RESEARCH STUDIES

The Observational Studies Will Collect Advanced Biometric Data in Upcoming Depression and PTSD Studies

Vancouver, British Columbia, October 19, 2021 / Globe Newswire / – KetamineOne Capital Limited (“Ketamine One” or the “Company”) (NEO: MEDI) (OTC: KONEF) (Frankfurt: MY0), a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments, is pleased to announce that it will be conducting its previously announced single arm, observational, biometric research studies (the “**Research Studies**”) in association with Biostrap USA, LLC (“**Biostrap**”) across multiple locations in Canada and the United States. Biostrap offers clinically validated wearable devices and a remote monitoring platform that utilizes science-driven artificial intelligence (“**AI**”) in combination with state-of-the-art health analytics and personalized actionable insights.

The Research Studies are the first of their kind and will involve the collection of real-time, advanced data from 200 patients to gain insights into depression and post-traumatic stress disorder. Biostrap’s devices measure oxygen saturation, respiration rate, heart rate variability, heart rate, sleep analysis, arterial health, and more. The data derived from the Research Studies will be analyzed with the aim of identifying biometric signatures that arise over the course of ketamine treatments, which may eventually aid physicians in making better dosage and timing decisions as well as reducing the chance of relapse for their patients.

Upon completion of the Research Studies, Ketamine One will have the opportunity to implement a proprietary interactive dashboard and data management tool. It will have the ability to analyze, monitor and visually display key ketamine treatment outcomes, while allowing clinicians to interact with the data and enabling them to make well-informed decisions. Clinicians will have the ability to track patient biometrics, medically validate outcomes, and become informed of AI-based depression predictions in order to enhance the treatment experience while increasing patient safety.

Becoming a more data-driven mental health organization will enable Ketamine One to produce better treatment outcomes and leverage it as a competitive advantage in the market. In preparation

for the rollout of Biostrap's clinically validated wearable devices, the Company has implemented advanced endpoint exploit and ransomware protection and other network security solutions to ensure data privacy and the security of patient information. Ketamine One staff have also undergone HIPAA training and certification, and the Company is fully compliant with data privacy and security standards in the United States and Canada.

Management Commentary

"While various studies have validated the efficacy of Ketamine therapy for the treatment of mood disorders including depression, few to none have characterized the individual physiological responses associated," said Kevin Longoria, Chief Science Officer at Biostrap. "By incorporating clinically validated digital health technology such as the Biostrap, researchers have the ability to better understand the dose-response relationship on the path to developing precision treatment protocols to optimize patient outcomes and safety. The potential of this relationship goes beyond research with practical applications related to early detection of physiological changes that may prompt follow-up treatments," added Longoria.

"The advent of AI and machine learning algorithms has spurred incredible advances in the predictive power of wearable health tracking devices and neurocognitive tests. The convergence of these technologies with patient-reported outcomes via mobile apps now provides a wealth of data that was not available to physicians even a few years ago," said Adam Deffett, Interim CEO of Ketamine One. "We are excited to conduct the Research Studies and I would like to thank Biostrap for their involvement and support thus far. This is a significant opportunity to work together to learn more about depression and post-traumatic stress disorder, and also work towards a purpose driven digital therapeutic tool" added Mr. Deffett.

ABOUT BIOSTRAP

Biostrap is a science-driven platform developed to improve and optimize human health. Facilitating data collection through a proprietary and clinically reliable wrist-worn device, Biostrap utilizes machine learning to provide actionable data to improve sleep, recovery and performance. Biostrap analyzes each heartbeat for 29 unique parameters on its secure servers to ensure data reliability. Biostrap is referenced in 14 publications and has 22 clinical studies validating its biometric measurements against gold standard medical diagnostics and use cases in specific medical conditions. Providing an individualized approach to consumers via an app and web dashboard, Biostrap also delivers customizable remote monitoring solutions for medical, clinical and fitness professionals. With its Biostrap Labs research division, Biostrap offers wellness companies the opportunity to validate the efficacy of their products and services in a real-world setting.

For further information about Biostrap, contact Klaudia Balogh, Media Manager, by email at klaudia@biostrap.com or visit its website at www.biostrap.com.

ABOUT KETAMINE ONE

KetamineOne Capital Limited is a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments. It is working to provide the critical infrastructure needed to develop and deliver breakthrough mental health treatments. Currently, Ketamine One has a network of clinics across North America, with plans to further consolidate the highly fragmented industry. The recent addition of KGK Science Inc. as the Company's contract research division also places the company at the forefront of premium clinical research based on its extensive experience in pharmaceuticals, cannabis, and the emerging psychedelic medicine industries. As a collective enterprise, Ketamine One is dedicated to helping solve the growing need for safe and accessible mental health therapy.

On behalf of:

KETAMINE ONE

"Adam Deffett"

Adam Deffett, Interim CEO

For further information, please contact:

Nick Kuzyk, Investor Relations

Tel: 1-844-PHONE-K1 (1-844-746-6351)

Email: IR@ketamine.one

Web: www.ketamine.one

Twitter: [@KetamineOne](https://twitter.com/KetamineOne)

Notice Regarding Forward-Looking Information:

This news release contains forward-looking statements including but not limited to statements regarding the Company's business, assets or investments, as well as other statements that are not historical facts. Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties, both general and specific, that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will not occur, which may cause actual performance and results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward-looking statements. These assumptions, risks and uncertainties include, among other things, the state of the economy in general and capital markets in particular, investor interest in the business and future prospects of the Company.

The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities law. Additionally, the Company undertakes no obligation to comment on the expectations of, or statements made, by third parties in respect of the matters discussed above.